Cargando…

Telmisartan and Rosuvastatin Synergistically Ameliorate Dementia and Cognitive Impairment in Older Hypertensive Patients With Apolipoprotein E Genotype

Objective: To investigate the effect of telmisartan, rosuvastatin, or their combination on dementia and to understand the impact of apolipoprotein E (APOE) genotype on the effect of the medications in older patients with hypertension. Methods: This is a double-blind, randomized, and placebo-controll...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Wenjing, Li, Ying, Zhao, Yingxin, Dong, Yuanli, Cui, Yi, Sun, Shangwen, Gong, Gary, Zhang, Hua, Chai, Qiang, Wang, Juan, Liu, Zhendong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7296075/
https://www.ncbi.nlm.nih.gov/pubmed/32581766
http://dx.doi.org/10.3389/fnagi.2020.00154
_version_ 1783546773355102208
author Hu, Wenjing
Li, Ying
Zhao, Yingxin
Dong, Yuanli
Cui, Yi
Sun, Shangwen
Gong, Gary
Zhang, Hua
Chai, Qiang
Wang, Juan
Liu, Zhendong
author_facet Hu, Wenjing
Li, Ying
Zhao, Yingxin
Dong, Yuanli
Cui, Yi
Sun, Shangwen
Gong, Gary
Zhang, Hua
Chai, Qiang
Wang, Juan
Liu, Zhendong
author_sort Hu, Wenjing
collection PubMed
description Objective: To investigate the effect of telmisartan, rosuvastatin, or their combination on dementia and to understand the impact of apolipoprotein E (APOE) genotype on the effect of the medications in older patients with hypertension. Methods: This is a double-blind, randomized, and placebo-controlled trial using a 2 × 2 factorial design. Between April 2008 and November 2010, 1,244 hypertensive patients aged ≥60 years without cognitive impairment were recruited from communities in six cities in Shandong area, China. Patients were randomized into telmisartan and rosuvastatin administration after a 2-week washout period. APOE genotype was identified at the baseline. Possible dementia was determined using the combination of the global cognitive function and Assessment of the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE). Results: Over an average follow-up of 7 [interquartile range (IQR): 6.7–7.2] years, telmisartan and rosuvastatin significantly reduced the cognitive impairment progression and the incidence of dementia. There was a synergistic interaction between telmisartan and rosuvastatin to reduce the cognitive impairment and the incidence of dementia (P(adjusted) < 0.001). The cognitive impairment progression and the risk of dementia were higher in the hypertensive patients with APOE ε4 allele than in those without APOE ε4 allele. Rosuvastatin medication significantly alleviated the cognitive impairment progression and the risks of dementia in patients with APOE ε4 allele. Conclusion: The combination of telmisartan and rosuvastatin might be an effective prevention and/or treatment strategy for cognitive impairment and dementia, especially in hypertensive patients with the APOE ε4 allele. Clinical Trial Registration: www.ClinicalTrials.gov, ChiCTR.org.cn, identifier ChiCTR-IOR-17013557. Registered on April 12, 2017 – Retrospectively registered, http://www.chictr.org.cn/showproj.aspx?proj=23121
format Online
Article
Text
id pubmed-7296075
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-72960752020-06-23 Telmisartan and Rosuvastatin Synergistically Ameliorate Dementia and Cognitive Impairment in Older Hypertensive Patients With Apolipoprotein E Genotype Hu, Wenjing Li, Ying Zhao, Yingxin Dong, Yuanli Cui, Yi Sun, Shangwen Gong, Gary Zhang, Hua Chai, Qiang Wang, Juan Liu, Zhendong Front Aging Neurosci Neuroscience Objective: To investigate the effect of telmisartan, rosuvastatin, or their combination on dementia and to understand the impact of apolipoprotein E (APOE) genotype on the effect of the medications in older patients with hypertension. Methods: This is a double-blind, randomized, and placebo-controlled trial using a 2 × 2 factorial design. Between April 2008 and November 2010, 1,244 hypertensive patients aged ≥60 years without cognitive impairment were recruited from communities in six cities in Shandong area, China. Patients were randomized into telmisartan and rosuvastatin administration after a 2-week washout period. APOE genotype was identified at the baseline. Possible dementia was determined using the combination of the global cognitive function and Assessment of the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE). Results: Over an average follow-up of 7 [interquartile range (IQR): 6.7–7.2] years, telmisartan and rosuvastatin significantly reduced the cognitive impairment progression and the incidence of dementia. There was a synergistic interaction between telmisartan and rosuvastatin to reduce the cognitive impairment and the incidence of dementia (P(adjusted) < 0.001). The cognitive impairment progression and the risk of dementia were higher in the hypertensive patients with APOE ε4 allele than in those without APOE ε4 allele. Rosuvastatin medication significantly alleviated the cognitive impairment progression and the risks of dementia in patients with APOE ε4 allele. Conclusion: The combination of telmisartan and rosuvastatin might be an effective prevention and/or treatment strategy for cognitive impairment and dementia, especially in hypertensive patients with the APOE ε4 allele. Clinical Trial Registration: www.ClinicalTrials.gov, ChiCTR.org.cn, identifier ChiCTR-IOR-17013557. Registered on April 12, 2017 – Retrospectively registered, http://www.chictr.org.cn/showproj.aspx?proj=23121 Frontiers Media S.A. 2020-06-09 /pmc/articles/PMC7296075/ /pubmed/32581766 http://dx.doi.org/10.3389/fnagi.2020.00154 Text en Copyright © 2020 Hu, Li, Zhao, Dong, Cui, Sun, Gong, Zhang, Chai, Wang and Liu. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Hu, Wenjing
Li, Ying
Zhao, Yingxin
Dong, Yuanli
Cui, Yi
Sun, Shangwen
Gong, Gary
Zhang, Hua
Chai, Qiang
Wang, Juan
Liu, Zhendong
Telmisartan and Rosuvastatin Synergistically Ameliorate Dementia and Cognitive Impairment in Older Hypertensive Patients With Apolipoprotein E Genotype
title Telmisartan and Rosuvastatin Synergistically Ameliorate Dementia and Cognitive Impairment in Older Hypertensive Patients With Apolipoprotein E Genotype
title_full Telmisartan and Rosuvastatin Synergistically Ameliorate Dementia and Cognitive Impairment in Older Hypertensive Patients With Apolipoprotein E Genotype
title_fullStr Telmisartan and Rosuvastatin Synergistically Ameliorate Dementia and Cognitive Impairment in Older Hypertensive Patients With Apolipoprotein E Genotype
title_full_unstemmed Telmisartan and Rosuvastatin Synergistically Ameliorate Dementia and Cognitive Impairment in Older Hypertensive Patients With Apolipoprotein E Genotype
title_short Telmisartan and Rosuvastatin Synergistically Ameliorate Dementia and Cognitive Impairment in Older Hypertensive Patients With Apolipoprotein E Genotype
title_sort telmisartan and rosuvastatin synergistically ameliorate dementia and cognitive impairment in older hypertensive patients with apolipoprotein e genotype
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7296075/
https://www.ncbi.nlm.nih.gov/pubmed/32581766
http://dx.doi.org/10.3389/fnagi.2020.00154
work_keys_str_mv AT huwenjing telmisartanandrosuvastatinsynergisticallyamelioratedementiaandcognitiveimpairmentinolderhypertensivepatientswithapolipoproteinegenotype
AT liying telmisartanandrosuvastatinsynergisticallyamelioratedementiaandcognitiveimpairmentinolderhypertensivepatientswithapolipoproteinegenotype
AT zhaoyingxin telmisartanandrosuvastatinsynergisticallyamelioratedementiaandcognitiveimpairmentinolderhypertensivepatientswithapolipoproteinegenotype
AT dongyuanli telmisartanandrosuvastatinsynergisticallyamelioratedementiaandcognitiveimpairmentinolderhypertensivepatientswithapolipoproteinegenotype
AT cuiyi telmisartanandrosuvastatinsynergisticallyamelioratedementiaandcognitiveimpairmentinolderhypertensivepatientswithapolipoproteinegenotype
AT sunshangwen telmisartanandrosuvastatinsynergisticallyamelioratedementiaandcognitiveimpairmentinolderhypertensivepatientswithapolipoproteinegenotype
AT gonggary telmisartanandrosuvastatinsynergisticallyamelioratedementiaandcognitiveimpairmentinolderhypertensivepatientswithapolipoproteinegenotype
AT zhanghua telmisartanandrosuvastatinsynergisticallyamelioratedementiaandcognitiveimpairmentinolderhypertensivepatientswithapolipoproteinegenotype
AT chaiqiang telmisartanandrosuvastatinsynergisticallyamelioratedementiaandcognitiveimpairmentinolderhypertensivepatientswithapolipoproteinegenotype
AT wangjuan telmisartanandrosuvastatinsynergisticallyamelioratedementiaandcognitiveimpairmentinolderhypertensivepatientswithapolipoproteinegenotype
AT liuzhendong telmisartanandrosuvastatinsynergisticallyamelioratedementiaandcognitiveimpairmentinolderhypertensivepatientswithapolipoproteinegenotype